Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.53 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 2/20 | 0.35 |
| ▸ | GABRD | O14764 | 2/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL9402867 | 0.90 | TSHR (0.43) | TSHRTP53EGLN1EGLN3ALDH1A1 | |
| Crotonic Acid SCHEMBL16178258 | 0.89 | TSHR (0.40) | TSHRTP53EGLN1EGLN3ALDH1A1 | |
| Crotonic Acid SCHEMBL28083293 | 0.89 | TSHR (0.40) | TSHRTP53EGLN1EGLN3ALDH1A1 | |
| Crotonic Acid SCHEMBL16178256 | 0.89 | TSHR (0.40) | TSHRTP53EGLN1EGLN3ALDH1A1 | |
| SCHEMBL871351 | 0.87 | FFAR3 (0.43) | TSHRALDH1A1ALOX15PTGS1AKR1C3 | |
| SCHEMBL15042 | 0.87 | — | — | |
| SCHEMBL338643 | 0.87 | FFAR3 (0.43) | TSHRALDH1A1ALOX15PTGS1AKR1C3 | |
| SCHEMBL133954 | 0.87 | — | — | |
| SCHEMBL18814 | 0.87 | — | — | |
| SCHEMBL1396002 | 0.87 | FFAR3 (0.43) | TSHRALDH1A1ALOX15PTGS1AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233935-A1 | Methods for Fabrication of Antimicrobial Surfaces | RESEARCH FOUNDATION OF CITY UNIVERSITY OF NEW YORK (US) | 2009-09-17 | — | — | US | disclosed |
| EP-1562621-B1 | COMPOSITION FOR TREATING ICHTHYOSIS USING ANTITRYPSIN | ARRIVA PROMETIC INC (CA) | 2009-08-19 | — | — | EP | disclosed |
| EP-1945229-A2 | METHODS FOR FABRICATION OF ANTIMICROBIAL SURFACES | Research Foundation of the City University of New York (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20080095806-A1 | Composition And Method For Treating Inflammatory Diseases Using Protease Inhibitors | PROMETIC BIOSCIENCES, INC. (CA) | 2008-04-24 | — | — | US | disclosed |
| WO-2008018890-A2 | METHODS FOR FABRICATION OF ANTIMICROBIAL SURFACES | RESEARCH FOUNDATION OF CITY UNIVERSITY OF NEW YORK (US) | 2008-02-14 | — | — | WO | disclosed |
| WO-2005117955-A1 | TREATMENT OF ATOPIC DERMATITIS WITH UNGLYCOSYLATED ALPHA ONE-ANTITRYPSIN | ARRIVA PHARMACEUTICALS, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| EP-1562621-A1 | COMPOSITION AND METHOD FOR TREATING INFLAMMATORY DISEASES USING PROTEASE INHIBITORS | Arriva-Prometic Inc. (CA) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004045634-A1 | COMPOSITION AND METHOD FOR TREATING INFLAMMATORY DISEASES USING PROTEASE INHIBITORS | ARRIVA-PROMETIC INC. (CA) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233935-A1 | Methods for Fabrication of Antimicrobial Surfaces | ADH1A, ADH1C, HAO2 | TSHR 2444/4885TP53 4117/4885EGLN1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.